Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US OKs Datascope's second dialysis access product:

This article was originally published in Clinica

Executive Summary

Datascope has received US clearance to sell its second product for the dialysis access market. ProGuide is a chronic dialysis catheter for connecting a patient with end stage renal disease to a dialysis machine. Chronic dialysis catheters have an estimated worldwide market of more than $100m, said the Montvale, New Jersey firm. The company's first entered the dialysis access market in the US in March this year, when it launched its ProLumen thrombectomy device for removing blood clots from blocked dialysis access sites.

You may also be interested in...



FDA Warning Letter Slams Pfizer Site In India On Sterility Testing, Environmental Monitoring

Pfizer's third US FDA warning letter since 2018 goes to injectables site in Vizag, India; tells the company to up its game in sterility testing and in the microbiology lab.

Gilead Moves Into Microbiome In Deal With Second Genome

Gilead lands on Second Genome as its first partner to apply microbiome analysis to pipeline assets to look for biomarkers. Companies also team up on GI drug discovery.

Warning Letter Close-Outs – March 2020

The US FDA released five device-related close-out letters in March.

Topics

UsernamePublicRestriction

Register

MT060440

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel